Antibodies targeting the checkpoints PD-L1, PD-1 and CTLA-4 are currently being used or are in clinical trials for treating many cancers including CRC; however, there are a number of problems associated with treating cancer patients with immunotherapies. Here, CTLA4 is linked to cancer.